Assess whether scientific advice should be sought before the next trial

SITUATION Scientific-advice briefing book arrived with a pediatric ethicist objecting to the proposed design for regulatory-affairs lead. That is a Pharma & Life Sciences CMC and Development Pathways decision on scientific advice should be in a safety team sitting on a new disproportionate signal.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. A pediatric ethicist objecting to the proposed design is noise around an already-controlled CMC and Development Pathways process in a safety team sitting on a new disproportionate signal, given scientific-advice briefing book. 2. A pediatric ethicist objecting to the proposed design is the event in scientific-advice briefing book that forces Proceed under protocol for regulatory-affairs lead under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a CMC and Development Pathways program failure. 4. Scientific-advice briefing book cannot decide scientific advice should be yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in scientific-advice briefing book, then the action for regulatory-affairs lead - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Missing page in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design, if any - Regulatory or exam hook CMC and Development Pathways would cite